MedTrace Logo

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

NCT05958121 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-07-01

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.

Primary objectives:

* To determine the maximum tolerated doses and/or recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia)
* To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I/II)
* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)

Secondary objectives:

* To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I)
* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)
* To describe the PK of IMA402 as monotherapy and in combination (Phase I/II)

Conditions

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Interventions

DRUG

IMA402

IV infusions

DRUG

IMA402 and checkpoint inhibitor

IMA402 IV infusions and checkpoint inhibitor

DRUG

IMA402 and chemotherapy

IMA402 IV infusions and chemotherapy

DRUG

IMA402 and IMA401

IMA402 and IMA401 IV infusions

DRUG

IMA402 and monoclonal antibody

IMA402 IV infusions and monoclonal antibody

DRUG

IMA402 and chemotherapy +/- monoclonal antibody

IMA402 IV infusions and chemotherapy +/- monoclonal antibody

Sponsors & Collaborators

  • Immatics Biotechnologies GmbH

    lead INDUSTRY

Principal Investigators

  • Immatics Biotechnologies GmbH · Immatics Biotechnologies GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-09
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05958121 on ClinicalTrials.gov